Eplontersen China PK study

Study identifier:D8450C00006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase 1, Open-Label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability of Eplontersen Following Subcutaneous Administration of a Single Dose in Healthy Chinese Volunteers

Medical condition

Transthyretin-mediated Amyloidosis

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Eplontersen

Sex

All

Estimated Enrollment

12

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 16 Aug 2024
Estimated Primary Completion Date: 28 Oct 2024
Estimated Study Completion Date: 27 Dec 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria